VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vir Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.21+0.25 (+2.51%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Vir Biotechnology, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and collaboration revenue | $238.94M | -$41.00K | – | – | -$495.00K | -$70.00K | – | – | – | – | – | – | 100.0% | -48369.7% |
| Grant revenue | $11.00K | $12.00K | $310.00K | $305.00K | $183.00K | $1.24M | $1.10M | $2.09M | $2.13M | $5.17M | $7.19M | $6.74M | 0.0% | -94.0% |
| Other revenue | $0 | $0 | – | – | $1.53M | $1.86M | – | – | – | – | – | – | 0.0% | -100.0% |
| Other revenue | – | – | – | $0 | $1.53M | $1.86M | $865.00K | $1.39M | $886.00K | $52.19M | $744.00K | $289.00K | – | – |
| Collaboration revenue | – | – | – | -$65.00K | -$495.00K | -$70.00K | $10.41M | -$1.10M | $55.00K | -$987.00K | $8.86M | -$4.39M | – | – |
| Profit-sharing amount | – | – | – | – | – | – | $10.41M | -$1.10M | $55.00K | -$287.00K | $8.73M | -$6.04M | – | – |
| Profit-sharing amount previously constrained, released | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $124.00K | $1.65M | – | – |
| Profit-sharing amount constrained | – | – | – | – | – | – | $1.00K | $0 | $0 | -$700.00K | $0 | $0 | – | – |
| License Revenue | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Vir Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.